Stock Taper
IFRX
INFLARX N.V.
NASDAQ
$2.23
▼ DOWN 1.76% (-0.04)

KEY STATISTICS

Market Cap$328.46 M
52w High$2.95
52w Low$0.80
Dividend Yield
Frequency
P/E-4.21
Volume610.39K
Shares Out.147.29M

COMPANY

LEADERSHIP

Niels C. Riedemann
CHIEF EXECUTIVE
Niels C. Riedemann

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 7, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
65

PRICE TARGET

Target High$9.00
Target Low$9.00
Target Median$9.00
Target Consensus$9.00

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$6.06K
NOV
9
MON

PRICE

$2.23 ▼ DOWN 1.76% (−$0.04)
$2.20$2.25$2.30$2.359:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.23

About InflaRx N.V.

https://www.inflarx.de ↗

InflaRx N.V., a German and U.S.-based biopharma, develops C5a inhibitors like vilobelimab for autoimmune and inflammatory diseases, with multiple products in clinical trials.

INDUSTRY

Biotechnology

A PRODUCT INFLARX N.V. IS KNOWN FOR

Gohibic (vilobelimab)
Gohibic (vilobelimab)

Gohibic, a first-in-class monoclonal antibody by InflaRx, inhibits C5a to reduce inflammation and is authorized in the EU and EUA in the U.S. for treating critically ill COVID-19 ARDS patients.

Revenue by Geography

MapREGIONFY2022
GERMANY$4.9M
UNITED STATES$100K

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

DIRECTOR
Brudnick Richard
· 30.0K shares
2026-03-18
OFFICER: SEE REMARKS
OCarroll Derval
· 70.0K shares
2026-03-18
OFFICER: CHIEF FINANCIAL OFFICER
Taapken Thomas
· 210.0K shares
2026-03-18
OFFICER: CHIEF FINANCIAL OFFICER
Taapken Thomas
· 240.0K shares
2026-03-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OVERWEIGHT 1
STRONG BUY 1
MARKET PERFORM 1
5 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
STTK$7.04COMPARE
ARTV$11.09COMPARE
STRO$20.45COMPARE
CNTB$2.23COMPARE
KLRS$4.03COMPARE
IMA$5.34COMPARE
ATYR$0.54COMPARE
MGX$1.19COMPARE